Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized double-blind IV ABT-719 in acute kidney injury
2012-005710-19Phase 2Terminated
- Sponsor
- AbbVie Inc.
- Start
- Oct 2013
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of modimelanotide in acute kidney failure (AKF), sponsored by AbbVie Inc. Primary endpoint: Maximal change from baseline in urine NGAL. Started Oct 2013; status: terminated.
02
Drugs
modimelanotide
03
Conditions
acute kidney failure (AKF)
Beyond the preview
Go deeper on 2012-005710-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005710-19.